Bio-AMD, Inc.is positioned in the fast growing Point of Care (PoC) medical diagnostics sector more.
Bio-AMD has three PoC technologies in development, each using a technology platform to be applied into specific market segments more.
Our coagulation technology is in the feasibility stage of commercialization in conjunction with a global hematology major more, in line with our business model that avoids the costs and risks of “go-it-alone” development .
The PoC market is growing fast. Forecasters suggest 10% growth per annum over the next few years will make the total market global worth over $22 billion.
Diagnostic testing accounts for only a low single digit % of healthcare expenditure worldwide, yet influences around two thirds of healthcare decisions. Driven by patient need and cost savings, hand-held devices offering rapid diagnostic testing are replacing slow and expensive laboratory analysis across a widening range of indications more.